Navigation Links
NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
Date:10/21/2009

SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. (NGM), a private company dedicated to the discovery and development of novel biotherapeutics for the treatment of Type 2 diabetes and other metabolic diseases, today announced that Arthur D. Levinson, Ph.D., the Chairman of Genentech's Board of Directors, has been appointed to NGM's Board of Directors. Under Dr. Levinson's leadership as Chairman and Chief Executive Officer from 1995 to 2009, Genentech became a leading global therapeutics company that was widely recognized as the most innovative biotechnology company in the industry.

Founded in 2008, NGM has created a proprietary discovery platform and pipeline based on biological insights into the relationship between bariatric gastric bypass surgery and post-surgical resolution of Type 2 diabetes and other metabolic disorders. Dr. Levinson will join other distinguished advisors in guiding the Company's research, development and business strategies.

"NGM has the attributes and values that I believe are fundamental to building an innovative and sustainable biotechnology company," said Dr. Levinson. "The company's creative approach to scientific research should provide new insights into disease processes, and support the discovery of differentiated, clinically important medicines."

"Art's accomplishments and leadership during his thirty years at Genentech are legendary," said David V. Goeddel, Ph.D., NGM's Chairman and Chief Executive Officer. "His scientific and business acumen will be invaluable in shaping NGM's continued progress."

Dr. Levinson is currently the chairman of Genentech's Board of Directors, an advisor to Genentech's Research and Early Development center and a member of Roche's Scientific Resource Board. In addition, he will be nominated to the Board of Directors of Roche Holding Ltd. in March 2010. Among his significant commitments are his memberships on the Bo
'/>"/>

SOURCE NGM Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
2. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
9. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... TechTeam Global, Inc ., (Nasdaq: ... technology outsourcing and business process outsourcing services, announced ... director of global life sciences services. Roumans will ... ongoing capability enhancement in support of TechTeam,s life ... of experience in the life sciences industry, most ...
(Date:2/9/2010)... Feb. 9 Delcath ... medical technology company testing its proprietary treatment system ... announced today the signing of its first research, ... Hepatic Perfusion (PHP) System  (the Delcath PHP System™). ... exclusive right to market and sell the Delcath ...
(Date:2/9/2010)... Feb. 9 Visage Imaging®, Inc., ... PME), announces today John Danahy joins as ... With over 17 years in the healthcare IT industry, ... team. ,, Danahy was previously VP Sales of ... developed new business opportunities in the EMR market segment. ...
Breaking Medicine Technology:TechTeam Global Appoints Life Sciences Services Director 2TechTeam Global Appoints Life Sciences Services Director 3Delcath Signs First Partner Agreement in Asia 2Delcath Signs First Partner Agreement in Asia 3Delcath Signs First Partner Agreement in Asia 4Delcath Signs First Partner Agreement in Asia 5Visage Imaging Names John Danahy as General Manager North America, Sales and Services 2BIO key 28R 29 Selected as 2009 Industry Innovator in Biometrics by SC Magazine 11162 1BIO key 28R 29 Selected as 2009 Industry Innovator in Biometrics by SC Magazine 11162 2BIO key 28R 29 Selected as 2009 Industry Innovator in Biometrics by SC Magazine 11162 3Kampyle Experiences Record Growth in 2009 with 25 000 New Customers 63391 1Kampyle Experiences Record Growth in 2009 with 25 000 New Customers 63391 2Kampyle Experiences Record Growth in 2009 with 25 000 New Customers 63391 3Kampyle Experiences Record Growth in 2009 with 25 000 New Customers 63391 4Kampyle Experiences Record Growth in 2009 with 25 000 New Customers 63391 5Dermatologists Reach Skin Cancer Screening Milestone 63389 1Dermatologists Reach Skin Cancer Screening Milestone 63389 2Dermatologists Reach Skin Cancer Screening Milestone 63389 3
... - Results Show Good Distribution of Bevasiranib to Retina ... after a ... Health, Inc. (Amex: OPK ),today announced that a study ... siRNA (small,interfering RNA) agent is distributed throughout the eye, including,extensive ...
... Inc.,(Nasdaq: DCTH ) announced today that the St. ... Hospital & Health Network (St. Luke,s),has joined Delcath,s Phase ... in the liver using the Company,s,Percutaneous Hepatic Perfusion (PHP) ... agent melphalan. This Phase III multi-center,study is led by ...
Other Medicine Technology:Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye 2Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye 3Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 2Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 3
(Date:2/9/2010)... The Providence Service Corporation, one of ... nationwide, today announced that it plans to relocate its ... Providence , working with Peach Properties, will take over ... Broadway, adjacent to the new site of Tucson Electric ... Tucson ,s public companies side by side and ...
(Date:2/9/2010)... redesigned MxSecure, Inc. site: www.mxsecure.com . , ... ... -- Medical transcription services and EHR provider , MxSecure, ... , , , ,Improving Medical Practice Productivity from Day One. ... the focus of all the company,s products and services, from ...
(Date:2/9/2010)... insurance industry’s need for data-driven automation across all marketing, ... , ... Atlanta, GA ... service and process automation solutions to the health insurance ... with MedicareCRM. Through this partnership, Connecture and MedicareCRM ...
(Date:2/9/2010)... Doctors should consider preventive measures, study suggests , , TUESDAY, ... bowel disease are much more likely to develop blood ... suggests. , And that may make preventive drug treatment ... United Kingdom, compared data on 13,756 people who had ... not have it. None of the people were ...
(Date:2/9/2010)... wife owners of specialty cake bakery put on their "game faces" ... ... February 9, 2010 -- As the Saints and the Colts prepared ... and wife owners, Steven and Sophie Rojas Tallon, of Yummy ... in the NFL Super Bowl Tailgate Cake Contest on Sunday. Sophie ...
Breaking Medicine News(10 mins):Health News:Providence Service Corporation Relocates Corporate Headquarters to Downtown Tucson 2Health News:Providence Service Corporation Relocates Corporate Headquarters to Downtown Tucson 3Health News:Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity 2Health News:Connecture, Inc. Announces Partnership with MedicareCRM 2Health News:Connecture, Inc. Announces Partnership with MedicareCRM 3Health News:Inflammatory Bowel Ups Risk for Blood Clots 2Health News:Yummy Cakes and More Places 2nd in NFL Super Bowl Tailgate Cake Contest 2
... a new compound AN2690, that might help to attack ... crucial for the protein synthesis of fungal pathogens. ... researchers including Dickon Alley and Stephen Cusack at Anacor ... (EMBL) outstation in Grenoble, France. ,AN2690 interferes with ...
... Anglo-American company has been allowed to store white blood ... the US Food and Drug Administration. ,White ... system that defend the body against both infectious disease ... 480-millilitre of blood from interested healthy individuals and will ...
... welcomed the European Union (EU) Parliament's resolution to ban mercury ... to do likewise. ,Toxics Link and other ... ,The group had called upon governments across the world to ... Programme (UNEP) in February. ,In one of ...
... and other northern mid- and upper-latitude regions are playing ... thought , according to a study appearing in this ... light on the so-called missing carbon sink, concludes that ... of carbon dioxide from the atmosphere, thereby partially offsetting ...
... lady love Jenny McCarthy has revealed her plans about getting a ... couple will be spending as much time as possible on the ... sit and do nothing. Stare at the ocean and go 'ohhmmm, ... spending a lot of time with her beau on the beach, ...
... World Food Programme (WFP) has warned that continuing security problems ... in the west of the country where food stocks are ... soon see critical food supplies curtailed or interrupted. ... region of Afghanistan for four weeks due to insecurity. Unless ...
Other Medicine News:Health News:Researchers Devise New Compound to Treat Fungal Infections 2Health News:Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming 2Health News:Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming 3Health News:Insecurity Jepardising WFP Initiatives in Western Afghanistan 2
...
...
...
Solid blade speculum designed for both temporal and superior approach ocular surgery. Adjustable with thumb screw. Manufactured in titanium....
Medicine Products: